PTJ
ONC

Paul Tudor Jones’s BeOne Medicines Ltd ONC Stock Holding History

Paul Tudor Jones’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,075
Closed -$565K – 3872
2025
Q1 		$565K Buy
+2,075
New +$485K ﹤0.01% 2206
2023
Q4 		– Sell
-1,600
Closed -$288K – 2990
2023
Q3 		$288K Buy
+1,600
New +$317K ﹤0.01% 1945
2022
Q4 		– Sell
-2,400
Closed -$324K – 2931
2022
Q3 		$324K Buy
2,400
+782
+48% +$134K 0.01% 1740
2022
Q2 		$262K Buy
+1,618
New +$253K 0.01% 1653
2020
Q1 		– Sell
-1,283
Closed -$213K – 1381
2019
Q4 		$213K Buy
+1,283
New +$213K 0.01% 974

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paul Tudor Jones's ONC Position: Q2 2025 in Review

Paul Tudor Jones sold out of BeOne Medicines Ltd (ONC) in Q2 2025, closing a stake of 2,075 shares — an estimated $565K sold.

Paul Tudor Jones first reported a position in ONC in Q4 2019 and held it in 5 quarters. The position peaked at $565K in Q1 2025. 244 funds tracked by Wall St. Rank hold ONC as of Q2 2025.

  • Paul Tudor Jones reported no remaining BeOne Medicines Ltd position as of Q2 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 2,075 BeOne Medicines Ltd shares in Q2 2025, an estimated $565K.
  • Paul Tudor Jones first reported a position in BeOne Medicines Ltd in Q4 2019 and held it in 5 quarters.
  • Paul Tudor Jones's BeOne Medicines Ltd position peaked at $565K in Q1 2025.
  • 244 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2025.

Based on Tudor Investment Corp's 13F filing for Q2 2025, filed 14 Aug 2025.